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Abstract:  New developments in molecular neuropathology have evoked increased 
demands for postmortem human brain tissue. The New South Wales Tissue Resource 
Centre (TRC) at The University of Sydney has grown from a small tissue collection into 
one of the leading international brain banking facilities, which operates with best practice 
and quality control protocols. The focus of this tissue collection is on schizophrenia and 
allied disorders, alcohol use disorders and controls. This review highlights changes in 
TRC operational procedures dictated by modern neuroscience, and provides examples of 
applications of modern molecular techniques to study the neuropathogenesis of many 
different brain disorders. 
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1. Introduction  
Molecular age technology represents unique opportunities to look at what we know about normal 
and abnormal brain structure and function from a new angle. Advances in the fields of genomics and 
proteomics offer new ways to study the pathophysiology of illnesses such as schizophrenia, alcohol 
use disorders, brain tumors, inflammatory and degenerative brain disorders. Despite significant 
advances in other methodological approaches, access to postmortem human brain tissue is vital for 
further progression of our knowledge on molecular neuropathology. This review highlights how one 
brain bank has developed to help scientists learn more about molecular neuropathology of diseases. 
With joint efforts from researchers, clinicians, patients, granting bodies and the general public, the 
brain bank is a powerful resource enabling new discoveries at the frontiers of neuroscience. 
The last two decades have been marked by drastic developments in high throughput approaches in 
molecular neuroscience. The ‘neurogenomics’ and ‘neuroproteomics’ fields have evolved such that we 
now have the ability to screen and compare whole genomes and proteomes of specific brain regions 
[1]. Careful selection of study cohorts and attention to the quality markers of tissue samples can have a 
tremendous impact on the outcomes from any research based on molecular techniques. To be able to 
apply these new technologies to study the human brain, scientists require access to multiple samples of 
well characterized postmortem human brain tissue preserved by freezing at ultra-low temperatures (-70 
ºC to -85 ºC). However, until recently, the majority of hospital and university collections acquired 
mostly formalin-fixed brain tissue used primarily for diagnostic purposes. The urgent need for non-
fixed frozen postmortem brain material for research is apparent. 
A high worldwide prevalence of neurodegenerative diseases, alcohol use disorders and other 
psychiatric conditions including schizophrenia [2], has placed these illnesses at the front edge of 
neuroscience research. This trend has resulted in an increased demand for human brain tissue samples 
[3-5]. The acquisition of donors with an alcoholic or a psychiatric background, in particular, presents 
specific challenges. These patients are very often single, unemployed, live alone with minimal to no 
contact with their next-of-kin (NOK), and are at high risk of going missing or becoming homeless. 
Therefore, following the death of such patients, it is often very difficult to locate the NOK, thereby 
limiting the possibility of obtaining appropriate consent within an acceptable time frame. In addition, 
there are specific difficulties associated with obtaining satisfactory clinical information for 
neuropsychiatric characterization and diagnosis [5]. Retrospective characterization of cases requires 
additional resources and can be a limiting factor affecting the validity of any investigation using   
these cases. 
The availability of ‘normal control’ cases for comparative studies is often a limiting factor [3]. 
Tissue collections that originate from hospital autopsies are primarily focused on illness and do not 
often contain unaffected normal control cases, resulting in a shortfall. With molecular techniques 
requiring large numbers of cases to reach statistical significance, and a continuing decline in hospital 
autopsies around the world [6] the situation is made even more desperate for tissue banks. This has 
generated a growing interest in the improvement of human brain tissue banking practices, and the 
establishment of pre-mortem brain donor programs [3, 6]. 
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2. The New South Wales Tissue Resource Centre (TRC) 
In 1994 the Australian government provided funds to establish a number of brain banks in different 
states to encourage more studies in the important field of mental health disorders, one of which was the 
New South Wales Tissue Resource Centre (TRC). It has since grown from a small collection of mostly 
formalin-fixed human postmortem brain tissue samples used for intramural research projects, into one 
of the leading brain banking facilities globally. The TRC provides both fixed and freshly frozen human 
brain tissue for Australian and international investigators. The collection focuses on schizophrenia and 
allied disorders, and diseases related to alcohol use.  Importantly, the TRC also acquires ‘normal 
control’ cases, an invaluable comparison group. For all cases, inclusion and exclusion criteria are 
stringently applied [7]. Since its establishment, the TRC has supported around 280 tissue requests from 
120 different neuroscience research groups worldwide. The TRC maintains strong ethical principles, 
and policies and procedures have been developed to ensure that they reflect community standards and 
meet legal requirements. This includes the complex issue of obtaining consent from donors and their 
families. An independent Scientific Board reviews all tissue requests from researchers focusing on the 
scientific merit and feasibility of the projects. 
At present, the TRC has more than 550 cases available for research use. These include over 120 
well characterized controls, 116 cases with alcohol use disorder and related pathology, 90 psychiatric 
cases - including schizophrenia and schizoaffective disorders, and 44 motor neuron disease cases. 
There are also cases with Alzheimer type pathology, ischemic and vascular pathology, brain tumors 
and cases with mixed and rare neuropathology. 
The main source for the collection of cases is ‘at death’ donations by the NOK through the 
Department of Forensic Medicine in Sydney, Australia. Recent figures reviewed over a five year 
period (2002-07) reveal that 54% of the NOK agreed to donate the brain tissue of their relative 
(unpublished observations). The most common reasons offered for the donation were altruism and 
compliance with the known wishes of the deceased. In 1998, due to decreased autopsy rates and to 
obtain prospectively collected detailed information about donors, the first of our pre-mortem brain 
donor programs was established. The ‘Using Our Brains’ program invites people with no neurological 
or psychiatric illness (controls) to consent to brain donation after death. In 2002 the ‘Gift of Hope’ 
brain donor program was launched to recruit people with psychiatric illnesses, especially 
schizophrenia. 
3. Changing nature of tissue requests and operational protocols at the TRC 
At autopsy, the brain is processed according to a standardized protocol [7], which allows the 
neuropathological examination of each case, as well as ensuring that both fresh-frozen and formalin-
fixed tissue is available for research. Collection procedures and dissection protocols employed by the 
TRC have developed over time, based on feedback from neuroscientists using the tissues for research. 
Recent improvements in research methodologies have dictated changes in the requirements for a 
postmortem human brain tissue sample. In the 1990’s, 85% of projects supported by the TRC used 
formalin-fixed tissue, with under 10 cases per project requested on average. In the last five years 
(2003-08), however, over 80% of tissue requests received by the brain bank were for non-fixed fresh Int. J. Mol. Sci. 2009, 10                 
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frozen brain tissue, with 20 to 30 cases per disease group per project requested on average. 
Simultaneously, the size of tissue samples required has decreased dramatically from 5-10 grams per 
block in the 1990’s down to 0.1 gram of tissue required for today’s studies. To illustrate this point, in 
2007-08 the majority of the supported projects employed genomics (51%) and proteomics (24%) 
methodologies, all of which required: (a) large cohort sizes; (b) fresh frozen tissues; (c) highly specific 
areas of the brain (e.g. grey matter from the Broadman area 9); and (d) an average tissue sample size of 
0.1-0.2 grams. 
Therefore, over the years, the dissection protocol at time of donation, has changed from a simple 
procedure where only a few tissue blocks (if any) were frozen, to a state-of-the-art highly specialized 
and standardized dissection protocol with over 70 specific brain regions dissected freshly, and frozen 
separately [7]. Such protocols maximize the availability of specific frozen brain regions for research 
and minimize the handling and potential thawing of frozen tissue when it is being prepared for the 
researcher. Detailed documentation with photographic images of tissue blocks taken at the time of 
dissection, are invaluable in assessing tissue availability and assisting staff when the request is being 
processed. The importance of appropriate qualifications and provision of ongoing training for staff 
members of the TRC cannot be overstated. 
The increased specificity of frozen tissue requests introduces an additional challenge for brain 
banking. Using highly sensitive molecular biology techniques, researchers now aim for very specific 
and macroscopically small brain regions. In contrast to gross anatomical regions, e.g. ‘hippocampus’, 
in order to address relevant biological questions, neuroscientists now often require specific brain 
regions, e.g. ‘hippocampal CA1 region from the anterior hippocampus at the level of the uncus’. In this 
respect, the contribution of the brain bank to a given research project can go significantly beyond just 
providing the tissues. Highly qualified staff thoroughly evaluates every tissue request to ensure that the 
appropriate brain area is available for the study cohorts, and most importantly that all samples 
provided are comparable between and within the study cohorts. Processing of such tissue requests can 
take considerable time and effort, but it is a key component for the success of any well-planned 
investigation. Providing tissue for the multiple tissue requests received, inevitably leads to ever-
changing availability of the different brain regions stored at the brain bank at any given time. Detailed 
tissue database records including digital photographs are essential so that tissue availability can be 
readily retrieved from a database reducing unnecessary handling of frozen material. 
 
4. Tissue integrity and clinical information quality assurance 
 
New molecular techniques dictate a need for the highest standards in the quality of the samples. 
There are numerous confounding pre- and post-mortem factors that are thought to play a role [8-12]. 
The most important factor affecting gene expression in postmortem human brain tissue is believed to 
be the total RNA quality [9]. In addition, other factors which must be considered are tissue pH, 
postmortem interval, age, agonal state and smoking history [8, 9]. These factors must be taken into 
account when selecting cases for the study cohorts. From the brain bank’s point of view, this 
emphasizes two main issues: tissue quality assurance (the tissue integrity domain) and case selection 
and characterization (the clinical domain).  Int. J. Mol. Sci. 2009, 10                 
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4.1. Tissue integrity domain 
The TRC measures brain tissue pH as part of the standard brain banking protocol [7, 13]. This data 
together with the results of detailed macroscopic and microscopic neuropathological examination is 
made available to researchers. The total RNA yield and quality data, however, is obtained from 
researchers who are using the tissue. RNA integrity may vary between the different brain regions even 
within the same case [8, 9]. It may also vary within the same region over time following tissue 
handling and due to temperature fluctuations when the same tissue block is used to obtain samples for 
multiple requests. Thus, the feedback from researchers using these tissues is very useful in establishing 
the best quality tissue. It also confirms the efficacy of the existing TRC protocols. Such a cost-
effective approach generates a comprehensive dataset for every case, on the most valuable and relevant 
brain regions that otherwise would be not assessed. Importantly, RNA integrity is assessed by a 
number of separate and independent research laboratories with expertise in the field, and the integrity 
assessment is performed longitudinally. This not only gives us objective feedback on tissue integrity, 
but also limits any potential artifacts or cases of mistaken poor RNA extractions. Taken together, the 
brain tissue pH, neuropathological diagnosis and RNA integrity data allow the TRC to select high 
quality research material.  
Based on evaluations received from researchers in the 2007-08 period, 96% of researchers 
commented on the high quality of the frozen tissue and RNA integrity from the samples provided by 
the TRC. Notably some of these samples had been stored for up to 12 years without degradation of 
tissue quality. However, the preparation of synaptosomes with intact morphology from frozen tissues 
is compromised (unpublished observations) due to the damaging effects of rapid freezing on 
membrane structures [14]. The cases with lower tissue integrity that are excluded from mainstream 
research are also precious and in high demand by researchers for the development and testing of new 
methodologies. The TRC assists with 10-20 requests for ‘trial’ tissue annually. 
4.2. Clinical domain 
The TRC operates with standardized clinical information collection protocols that have evolved 
over many years. Humans are ‘difficult’ subjects to study: we cannot control their environment, diet, 
lifestyle, habits, the illnesses they may develop, how they are treated, or ultimately how they die. 
Researchers need to be aware of the multitude of pre-mortem factors that can influence their data. The 
clinical domain therefore provides another significant area of input by the TRC into supported research 
projects. In-depth retrospective clinical and lifestyle characterization of cases following the death of a 
donor is a time-consuming exercise and requires specialist staff. However, without adequate clinical 
information, it is not possible to select and match cases appropriately for various study cohorts. 
A sound, reliable psychiatric diagnosis is critical for brain banking facilities such as the TRC, which 
aims specifically to support research into psychiatric illnesses and alcohol use disorders. All 
psychiatric or alcohol use disorder diagnoses are confirmed retrospectively using the Diagnostic 
Instrument for Brain Studies – Revised (DIBS-R) [15]. The DIBS is semi-structured instrument 
designed specifically for post-mortem psychiatric assessment using medical records and informants Int. J. Mol. Sci. 2009, 10                 
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where available. This instrument is compliant with the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV) [16] and has demonstrated reliability [17]. 
The DSM-IV diagnosis assigned to each case (derived from the DIBS) is based on a detailed and 
standardized clinical assessment summary created by specially trained staff with a background in 
psychiatry and/or psychology. The structure of this summary readily allows assessment of diagnostic 
inter-rater reliability. Control cases are characterized using the same process as employed for 
psychiatric cases, to ensure appropriate use of each case in a comparison group. A recent 
comprehensive assessment of the reliability of postmortem TRC psychiatric diagnoses, relative to 
lifetime (ante-mortem) diagnoses from medical records, showed moderate to excellent inter-rater 
reliability for most cohorts. There was sufficient disagreement, however, particularly in relation to the 
schizoaffective disorder cohort, to highlight the importance of a standardized approach to psychiatric 
diagnosis. Also illustrated in this study was the importance of accurate medical record keeping at a 
symptom-based level [18]. 
The initial body of information collected on cases in the mid 90’s rarely included comprehensive 
lifestyle information. Now, however, the TRC specifically aims to collect information on factors such 
as medications, illicit drug use, and alcohol and tobacco use for every case. During the last three years, 
all requests for tissues from psychiatric cases sought detailed information - not only regarding the age 
of disease onset and duration of illness, but also on the antipsychotic drug treatments prescribed, 
including the predominant type of antipsychotics used, and an estimate of the lifetime chlorpromazine 
equivalent medication dosages. Details of tobacco and alcohol use in both the study and control groups 
are also sought by almost 100% of researchers requesting tissue. Along with the cause of death, other 
autopsy findings such as toxicology reports and liver pathology are also frequently asked by 
researchers. The ability to operate with these facts and to cross-correlate research findings with clinical 
and lifestyle information is a powerful tool in molecular type studies [19, 20]. 
 
5. Evolution of the TRC 
 
Brain banking is necessarily a long-term project and requires continued commitment from 
institutions and staff, as well as considerable infrastructural financial support. The numbers of cases 
collected each year have grown from just over 25 cases per year in the 90’s to ~65 in 2008. In the first 
five years (1994-99) the TRC fulfilled a total of 34 tissue requests, almost all (~90%) of which were 
from researchers associated directly with the brain bank. The majority of these early projects were 
related to alcohol and schizophrenia research. By comparison, during the last five years (2003-08), the 
TRC has fulfilled on average 34 research projects each year. In 2008, approximately one third of 
requests arose from researchers directly associated with the brain bank, while the remainder came from 
external research groups - including 25% of requests from international researchers. While the 
‘traditional’ research focus on schizophrenia (39% of requests in 2008) and alcohol-related disorders 
(31%) is maintained, there are a growing number of research projects in other fields (30%). The latter 
group includes projects on neurodegenerative diseases, as well as basic neuroscience investigations 
into brain structure and function. The most requested case types from the TRC for these studies are 
controls (see below). With the publication of research outcomes from studies using TRC-sourced 
tissues, there is mounting demand for postmortem human brain tissue from our facility. Although the Int. J. Mol. Sci. 2009, 10                 
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TRC strongly preserves its focus on schizophrenia and allied disorders, as well as alcohol-related 
diseases, the expansion of its role beyond this focus is evident. Fortunately, there is strong public 
interest in brain donation, and the number of people expressing their willingness to consent pre-
mortem is growing.  
The maintenance of brain banking resources and pre-mortem brain donor programs comes at a high 
cost. Each brain successfully banked and made available for research costs at least A$15,000 or more. 
This includes costs associated with employment and training of administrative, technical, clinical and 
research staff, as well as neuropathologists. Costs for body transport and technical assistance for 
autopsies are often forgotten. There are other costs associated with maintenance of storage facilities 
and laboratories, consumables, databases and web-based information systems. Funding is difficult to 
obtain from competitive granting bodies since it is not ‘project driven’ research. Thus, brain banks are 
largely reliant upon government bodies to provide the infrastructural support. Brain banks should be 
seen in the same light as preventative medicine programs. Given the emerging technologies that can be 
applied to appropriately-stored human brain tissue and the burden of mental health disorders in our 
society we must ensure that researchers can be provided with high quality human brain tissue. The 
planning and support that brain banking receives today will determine how well future progress in 
molecular neuroscience can be provided for. 
 
6. Australian Brain Bank Network 
 
Brain banks have been established in Australia and throughout the world to ensure a diverse 
collection of brain tissues. The recruitment and collection regimes for each of these banks are often 
developed independently, usually in order to facilitate the collection of cases for use by a bank’s own 
researchers. In Australia, brain donor programs and brain banks have been established in five state 
capital cities. In 2003, the National Health and Medical Research Council of Australia funded a grant 
enabling these brain banks to liaise with one another as the Australian Brain Bank Network (ABBN). 
The ABBN ensures the availability of a greater number and range of human brain tissues for 
researchers (http://www.nnf.com.au/platforms/abbn/). By 2008, a total collection of more than 1,800 
cases has been made available for research. Each ABBN brain bank employs standardized protocols, 
so that tissue provided by any site is comparable in its preparation and storage methodologies. 
Compared with published methodologies of other international brain banks, the ABBN operations are 
in line with the best known practices [3, 21-23]. 
 
7. Specific examples of molecular neuropathological studies using TRC tissues 
 
Any tissue request received by the TRC undergoes a thorough review process (Figure 1) by a 
Scientific Advisory Committee, consisting of independent scientists and clinicians with proven 
expertise in related research areas, as well as the TRC directors and representatives. The review 
process that usually takes two to three weeks includes: (a) scientific merit; (b) proof of methodology; 
(c) track record; (d) ethical compliance; (e) tissue availability; (f) potential conflict of interest; and (g) 
justification of the region, type and amount of human brain tissue requested.  Int. J. Mol. Sci. 2009, 10                 
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Figure 1. A flow-chart of the tissue request process at the TRC. Colors represent different 
domains in the request process: green – a researcher’s domain; yellow – the TRC domain; 
blue – a successful tissue request; and red – an unsuccessful tissue request. 
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7.1. Schizophrenia 
 
The pathophysiology of schizophrenia involves the alterations in neurotransmitter systems such as 
dopamine, glutamate, GABA-ergic, serotonergic and cholinergic to name the few. Although the 
diagnosis of schizophrenia is primarily phenomenological, the neuroanatomical changes are believed 
to be widespread, largely involving impaired neural circuitry between and within prefrontal and 
temporal cortices, limbic system and the midbrain. The cohorts collected by the TRC have been 
successfully used in studies aiming to understand specific molecular mechanisms or systems 
responsible for schizophrenia. 
Proteomics allows changes in the global protein expression and modification to be investigated and 
allows us to picture the translation of genomic information together with co- and post-translational 
modifications [24]. The brain proteome profiles of two regions, the anterior cingulate cortex (ACC) 
and the genu of the corpus callosum (CС), from the schizophrenia and control cohorts have been 
compared [24-26]. For such studies, which screen large pools of proteins, it is imperative to eliminate 
any false positives due to pre- or post-mortem factors or due to the brain proteome regional 
differences. By using exactly the same cohorts in three different proteomic investigations, scientists 
could cross-correlate their findings and identify key proteins, the changes in the expression of which 
are most likely to be related to the schizophrenia neuropathogenesis. The later included proteins 
involved in metabolism, cytoskeleton, oxidative stress, synaptic and neuroprotective function. There 
was some overlap in protein candidates, but the majority of the altered proteins were region-specific 
[25, 26]. Furthermore, within the same regions of interest, the identified proteins were different when 
compared separately within the left or right hemisphere [26], and also within adjacent grey or white 
matter regions [25]. This fact prompted further proteomic investigations, e.g. how the grey and white 
matter proteomes differ from each other in normal controls [27]. 
Specific protein markers of the biological pathways involved in schizophrenia is another area where 
autopsy material is indispensable. Disturbances in cognition in schizophrenia, particularly in relation to 
motivation and attention, have attracted specific attention to the ACC. Receptor binding studies 
implicated imbalance of neurotransmitter regulation in schizophrenia, e.g. impaired endogenous 
cannabinoid system, glutamatergic and cholinergic muscarinic receptors in the ACC [28-33]. 
Furthermore, significantly reduced expression of human neuronal protein 22 (hNP22) in the ACC 
ndicates aberrant neuronal cytoarchitecture and dysregulation of neural signal transduction in 
schizophrenia [34]. 
The posterior cingulate cortex (PCC) in the limbic system is sensitive to MNDA receptor 
antagonists and is important for working memory. In schizophrenia, the PCC displays reduced 
metabolism and slow activation. As shown using the TRC cohorts, there are reductions in regional 
volumes and gyral folding of the PCC in schizophrenia [35]. A number of studies investigated this 
brain region by quantitative autoradiography. These studies showed abnormal expression of glutamate, 
GABA, muscarinic, and cannabinoid receptors, suggesting an increased acetylcholine and down 
regulated GABA stimulation in the PCC in schizophrenia [36-38]. The significant overlap of the 
cohorts used by these separate studies allows them to be compared directly. Furthermore, the use of the 
comprehensive clinical information available on antipsychotic drug treatments and cannabis use allows 
clinical correlations to be taken into account. Int. J. Mol. Sci. 2009, 10                 
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Pioneering investigations into the distribution of the tachykinin receptors, which play a role in 
inflammation and autonomic reflexes, have discovered increased neurokinin-1 receptor 
immunoreactivity in the prefrontal cortex (PFC) [39-41]. Despite the TRC providing the PFC and 
anterior hippocampus (HP) from carefully matched cohorts, a novel theory of reduced AKT-GSK3β 
molecular cascade signaling in schizophrenia was unable to be confirmed [42]. The same study did 
also show that phosphorylation levels of proteins in the postmortem brain can be correlated with PMI 
and tissue pH [42]. Calcium signaling has a vital role in neuronal signal transduction that is thought to 
be altered in schizophrenia. Other studies have been examining the contributions of specific calcium 
binding proteins (calbindin, calretinin and parvalbumin) to the molecular neuropathogenesis in the 
PFC and PCC of schizophrenia cases obtained from TRC cohorts [43, 44]. The superior temporal 
gyrus (STG) is a major anatomical substrate for speech, language and communication, all of which are 
disturbed in schizophrenia. By studying the STG, Deng and Huang [45, 46] elucidated molecular 
mechanisms that may be responsible for auditory hallucinations in schizophrenia. They reported an 
abnormal interaction between GABA receptors and various muscarinic receptors subtypes [45, 46]. 
The TRC has provided tissues for studies aiming to investigate changes in genes in schizophrenia. 
Altered gene expression in the STG in schizophrenia includes those involved in neurotransmission and 
neurodevelopment, and to a lesser extent presynaptic function [47]. Decreased STG expression of the 
regulator of G-protein signalling 4 (RGS4) mRNA in schizophrenia supports RGS4 as a potential 
genetic and functional biological marker of schizophrenia [48]. Furthermore, analysis of global 
miRNA expression in STG cortical grey matter reveals significant up-regulation of miR-181b 
expression in schizophrenia. This miRNA is predicted to regulate many target genes including calcium 
sensor gene visinin-like 1 and the ionotropic AMPA glutamate receptor subunit (GRIA2), both of 
which are found to be down-regulated in the same tissue [49]. A possible link between schizophrenia 
and NMDA-glycine site receptor ligand metabolic enzymes, D-amino acid oxidase and kynurenine 
aminotransferase-1 was demonstrated in cerebellum and parietal cortex using TRC cohorts [50]. 
Schizophrenia-related changes in the amygdala genome include genes involved in synaptic 
function, myelination and cellular signaling [51]. However, there is no amygdale-specific 
tachykininin-binding NK1 receptor contribution to the schizophrenia pathogenesis [52]. Further studies 
into molecular biological basis of schizophrenia and allied disorders using the TRC cohorts   
are warranted.  
7.2. Alcohol use disorders 
Research studies performed over the past ten years using the TRC tissue identified alcohol-
responsive genes in different brain regions [53, 54]. The TRC study cohorts have included both non-
cirrhotic and cirrhotic cases. Most recently, studies have also considered the combined effects with 
nicotine use. 
Of 4000 target genes screened in the superior frontal cortex (SFC), 163 genes had altered 
expression in brain tissue from alcoholics [55]. These included genes associated with white matter, e.g. 
down-regulated myelin-related genes [56]. There is also down-regulation in the expression of genes 
involved in protein trafficking, cytoskeletal organization, plasma membrane recycling, protein sorting, 
synaptogenesis and synaptic plasticity [57]. The genes involved in calcium, cAMP, and thyroid Int. J. Mol. Sci. 2009, 10                 
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signaling pathways are also altered in the brain due to alcohol abuse. The frontal and the motor cortex 
display widespread alterations in genes at transcriptional level [54]. A considerable alcohol-induced 
reprogramming of gene expression in the SFC occurs in genes not only involved in myelination and 
neurogenesis, but also in genes involved in ubiquitination, apoptosis, cell adhesion, and in 
neurodegenerative diseases, which suggests a link between alcoholism and other neurodegenerative 
conditions [58]. The neural adaptations to alcohol on cellular level also include an inhibition of protein 
and mRNA expression levels of intrinsic apoptotic pathways in the PFC in alcoholics [59], which 
reflects on the decreased cell density in this region [60, 61]. 
The mesocorticolimbic dopaminergic system, arising in the ventral tegmental area (VTA) and 
projecting to the nucleus accumbens (NA), the amygdala, the septum and the PFC, is a recognized 
reward pathway for drugs of abuse such as alcohol [53]. Examining this pathway, only 13 out of a total 
of 230 genes with altered expression were common between the NA and the PFC suggesting that 
alcoholism may be associated with adaptive changes specific to regions [62]. Further investigations 
showed alcohol-responsive genes in the NA and the VTA that primarily were associated with changes 
in neurotransmission and signal transduction [63]. A number of early gene expression profile studies in 
alcohol abuse did not consider the variable of nicotine use and this may explain the discrepancy in 
results of those using different cohorts [55, 57, 62]. However, long-term alcohol abuse, heavy smoking 
and co-abuse can have a selective impact on gene expression as has been demonstrated in the PFC and 
VTA regions [19, 20]. Consideration of different environmental and pathological conditions must be 
incorporated into the gene expression studies [19, 64, 65]. Complications of alcohol abuse such as liver 
cirrhosis are associated with widespread effects on the transcriptome of whole groups of genes (as 
compared with non-cirrhotic alcoholics), in particular genes involved in cell adhesion, mitochondrial 
function, synaptic transmission, apoptosis, and cell proliferation [66]. 
Neuroadaptations to the effects of chronic alcohol consumption include dysregulation of 
transcription factors of the NF-κB (Nuclear Factor-kappaB) family, which have implications for 
neuronal plasticity and neurodegeneration [67]. Elevated levels of synaptophysin I suggest a role in the 
enduring neuroplasticity in the prefrontal cortical glutamate circuitry that is associated with ethanol 
dependence [68]. 
On the proteome level, alcohol causes global changes in the expression of multiple proteins. In the 
superior frontal cortex, there were 182 proteins or protein isoforms with altered expression [69]. The 
majority of these (139) had lower expression levels in the alcoholic brain. In the PFC, 60 proteins 
change their expression characteristics in white matter with alcohol abuse compared with 44 identified 
in grey matter. The functional groups of the altered proteins included carbohydrate and protein 
metabolism, signal transduction/cell communication, cytoskeleton and homeostasis [70, 71]. Amongst 
changed proteins thiamine dependent enzymes transketolase and pyruvate dehydrogenase (E1ß 
subunit) are disturbed, even in “neurologically uncomplicated” alcoholics [72]. Cortical layers of the 
frontal cortex in alcoholics also showed increased levels of hNP22 protein, a cytoskeleton-interacting 
protein, which can be involved in morphological or plastic changes that are observed after chronic 
alcohol exposure and withdrawal [73]. An induction of two proteins, midkine and excitatory amino 
acid transporter 1, in the PFC of chronic alcoholics may reflect an adaptive reaction to accelerated 
neurodegeneration [19]. Proteomic investigations into the genu and splenium of the CC suggest that 
the mechanisms of alcohol-induced white matter damage may be different compared to the prefrontal Int. J. Mol. Sci. 2009, 10                 
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region [74, 75]. Proteins involved in oxidative stress, lipid peroxidation and apoptosis were specific to 
cirrhotic alcoholics [75]. Another region that is highly alcohol sensitive is the hippocampus [76] with 
17 different proteins showing alcohol-related altered expression.  
 
7.3. Movement disorders and dementias 
 
While movement disorders are not targeted by the TRC, brain and spinal cord donors who have 
Motor Neuron Disease (MND) are an exception. Using brain tissues provided by the TRC, researchers 
have excluded several possible causes of sporadic MND, including some viral infective agents [77], 
and impairment of methylation genes responsible for detoxifying the body from heavy metal exposure 
[78]. Blood samples of those with MND collected separately by the MND-DNA bank, in association 
with DNA obtained from brain tissues from the TRC, have expanded the types of studies able to be 
undertaken [79-81]. DNA studies from blood complement similar studies using brain tissues. More 
recent research in MND using TRC cases have been performed using microarray genotyping and other 
forms of gene analysis [82]. 
Parkinson’s disease is identified neuropathologically by the loss of pigmented neurons in the 
brainstem. These unique cells containing neuromelanin pigment are responsible for the black 
appearance of the substantia nigra in the brainstem. Studies using cases from the TRC and other 
sources have examined these dopaminergic pigmented neurons to ascertain the developmental stages 
of the neuromelanin pigment with normal aging [83, 84].  Such studies aid our basic understanding of 
human brain structure with age and in Parkinson’s disease. 
A number of studies have utilized TRC control tissues in studies of Alzheimer’s disease (AD) and 
other dementias. An early study by Cullen et al [85] showed changes in astrocytes surrounding the 
microvasculature occurring with plaque formation. This gives an insight into how plaques are formed 
in AD. Other early studies examined cell losses in differing brain regions in AD, as for example, in the 
basal forebrain [86]. Apolipoprotein E (ApoE) s a well-known risk factor gene for AD, and 
relationships with ApoE status have been performed comparing cases with AD with control cases 
using TRC tissues [87]. The ApoE ε4 allele is associated with the deposition of β-amyloid known to be 
a major component of AD, especially for late-onset AD. More recent studies are examining other 
genes known to be associated with AD, including early onset forms [88, 89]. The inflammatory 
response in AD is another area of study of importance to dementia researchers. The TRC tissue 
collection protocols, whereby cases and controls are collected with short PMI and good agonal state, 
are extremely helpful for these types of studies. A recent study identified a number of upregulated 
cytokines and chemokines that mediate the inflammatory response in AD [89]. 
Frontotemporal dementia and Lewy body dementia are also important areas of study that have 
significant clinical and pathological overlap with other dementing diseases. The accurate 
neuropathological characterization of cases by the brain bank is an extremely important role. For 
example, cases with frontotemporal dementia with motor neuron disease inclusions need to be 
differentiated from cases with motor neuron disease without dementia. Similarly, cases with Lewy 
body dementia need to be differentiated from both AD (which has dementia) and from Parkinson’s 
disease (which doesn’t). Such clinical and pathological differentiation allows researchers to study these Int. J. Mol. Sci. 2009, 10                 
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diseases on the molecular level. For example, tau deposition as part of the pathological presentation in 
frontotemporal dementia is not necessarily accompanied by altered tau gene expression [90]. 
 
8. Conclusions  
 
The severe, debilitating nature and high worldwide prevalence of brain diseases imposes great 
personal, social, clinical and economic consequences, resulting in these illnesses being amongst the 
leading causes for disability globally [2]. Investigating the neurobiological basis of these diseases in 
the ultimate search for improved diagnostics and treatments requires access to well characterized and 
well preserved postmortem human brain tissue. The New South Wales Tissue Resource Centre in 
Sydney has a specific focus on psychiatric conditions and controls, and operates using best practice 
and quality control protocols. Since its establishment the TRC has become a key resource facility with 
an international reputation. Tissue provided by the TRC has enabled many independent studies to 
utilize novel molecular age technology. The protocols and operational procedures employed by the 
TRC accommodate the varied demands dictated by modern neuroscience. The TRC, in association 
with the pre-mortem brain donor programs and the Australian Brain Bank Network, holds great 
promise for the future. 
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